ATHE vs ATOS

Alterity Therapeutics Limited vs Atossa Therapeutics, Inc. — Valuation Comparison 2026

ATHE

Biotechnology
Alterity Therapeutics Limited
Quality
1.8
out of 10
Value Trap
Price
$4.08
Last close
Models
8/13
Active
VS

ATOS

Biotechnology
Atossa Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$5.19
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ATHE Fair ValueATHE Upside ATOS Fair ValueATOS Upside
Bayesian DCF Intrinsic $1.08 -73.5% $3.40 -34.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.18 -95.5% $0.52 -90.2%
Dynamic NAV Asset-Based $1.07 -73.5% $5.90 +13.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATHE vs ATOS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATHE vs ATOS — Which Stock Is More Undervalued?

ATOS scores higher with a 4.5/10 quality rating vs ATHE's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alterity Therapeutics Limited (ATHE) and Atossa Therapeutics, Inc. (ATOS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATHE currently trades at $4.08 with a QOC of 1.8/10, while ATOS trades at $5.19 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).